ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Dr. Thomas Hutson on Drug Sequencing in Renal Cell Carcinoma

Thomas E. Hutson, DO, PharmD
Published: Friday, Apr 24, 2015



Thomas E. Hutson, DO, PharmD, medical oncologist, Director of Genito-Urinary at Texas Oncology–Baylor Charles A. Sammons Cancer Center, discusses drug sequencing for the treatment of renal cell carcinoma.

Seven new agents have been approved for renal cell over a relatively short period of time. That has made it difficult to determine which drugs should be used for first, says Hutson.

An evidence-based approach is the best way to determine which drugs will be the most effective in the frontline setting. Sunitinib and pazopanib both have drug evidence from phase III trials demonstrating great efficacy, safety, and tolerability and should be considered for the frontline setting for renal cell.



Thomas E. Hutson, DO, PharmD, medical oncologist, Director of Genito-Urinary at Texas Oncology–Baylor Charles A. Sammons Cancer Center, discusses drug sequencing for the treatment of renal cell carcinoma.

Seven new agents have been approved for renal cell over a relatively short period of time. That has made it difficult to determine which drugs should be used for first, says Hutson.

An evidence-based approach is the best way to determine which drugs will be the most effective in the frontline setting. Sunitinib and pazopanib both have drug evidence from phase III trials demonstrating great efficacy, safety, and tolerability and should be considered for the frontline setting for renal cell.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing Chemotherapy Induced Nausea and VomitingOct 31, 20182.0
Publication Bottom Border
Border Publication
x